[Inhibitor of apoptosis in lung cancer Livin perioperative clinical research].
To detect the inhibitor of apoptosis protein Livin in non-small cell lung cancer patients with perioperative serum levels were analyzed trends in perioperative period to explore the Livin in non-small cell lung cancer diagnosis, classification and prognosis of clinical significance. Enzyme-linked immunosorbent assay (ELISA) of 40 patients with non-small cell lung cancer patients before surgery, the serum levels of Livin expression and 20 cases of normal healthy human serum levels of Livin were detected. Non-small cell lung cancer patients was significantly higher than the level of serum Livin healthy control group. Before surgery (median 526.49 ng/L, quartile 357.93-825.57 ng/L), postoperative (median 286.49 ng/L, quartile 157.93-515.57 ng/L), there was significant difference between the two groups (P<0.05).Livin the average level of serum with non-small cell lung cancer the relationship between pathology: I, II period (median 326.49 ng/L, quartile 201.54-623.19 ng/L) and stage III (median 586.31 ng/L, quartile 411.79-965.34 ng/L) statistically significant difference between (P<0.05); tumor lymph node metastasis in 11 cases (median 562.03 ng/L, quartile 382.64-982.61 ng/L) and the 29 cases without lymph node metastasis (median 344.59 ng/L, quartile 167.27-646.20 ng/L) significant difference between (P<0.05); organization credits of: high, medium, poorly differentiated among the three groups without significant differences (P>0.05). Livin as a new inhibitor of apoptosis protein in non-small cell lung cancer diagnosis, staging has some clinical value.